Chaisrimaneepan Nattanicha, Thiravetyan Ben, Nakaphan Pannathorn, Puchongmart Chanokporn
Department of Internal Medicine, Texas Tech University Health Science Center, Lubbock, TX, USA.
Department of Internal Medicine, Weiss Memorial Hospital, Chicago, IL, USA.
J Scleroderma Relat Disord. 2025 May 20:23971983251342065. doi: 10.1177/23971983251342065.
The study was conducted to investigate the impact of systemic sclerosis (SSc) on hospitalized COVID-19 patients.
This retrospective observational study analyzed data from the National Inpatient Survey (NIS) in 2021. Patients hospitalized with COVID-19 were categorized into SSc and non-SSc groups. Characteristics of patients and comorbidities were compared. The primary outcome was the mortality rate. Secondary outcomes included resource utilization and acute in-hospital complications of SSc. Multivariate logistic regression analyses were conducted, with -values < 0.05 considered statistically significant.
Of all, 1865 patients hospitalized with COVID-19 had SSc. Patients with SSc had a higher mortality risk (aOR = 1.37 [1.03-1.82]; = 0.032). The average cost of hospitalization was significantly higher in the SSc group ( = 0.048), with no difference in LOS (9.4 ± 0.65 days vs 8.4 ± 0.03 days; = 0.260). COVID-19 patients with SSc significantly had a higher risk for DIC (aOR 2.82 [1.06-7.53]; = 0.038), left-sided HF (aOR 1.76 [1.16-2.67]; = 0.008), ventricular arrhythmia (aOR 3.17 [1.01-9.89]; = 0.047), oxygen dependence (aOR 2.41 [1.64-3.55]; < 0.001), cardiac arrest (aOR 2.61 [1.63-4.18]; < 0.001), and ileus (aOR 2.61 [1.45-4.69]; = 0.001).
Hospitalized COVID-19 patients with SSc were more likely to develop in-hospital complications and had a higher mortality risk.
本研究旨在调查系统性硬化症（SSc）对COVID-19住院患者的影响。
这项回顾性观察性研究分析了2021年全国住院患者调查（NIS）的数据。将COVID-19住院患者分为SSc组和非SSc组。比较患者的特征和合并症。主要结局是死亡率。次要结局包括SSc的资源利用情况和急性院内并发症。进行多因素逻辑回归分析，P值<0.05被认为具有统计学意义。
共有1865例COVID-19住院患者患有SSc。SSc患者的死亡风险更高（调整优势比[aOR]=1.37[1.03-1.82]；P=0.032）。SSc组的平均住院费用显著更高（P=0.048），住院时间无差异（9.4±0.65天 vs 8.4±0.03天；P=0.260）。患有SSc的COVID-19患者发生弥散性血管内凝血（DIC）的风险显著更高（aOR 2.82[1.06-7.53]；P=0.038）、左侧心力衰竭（aOR 1.76[1.16-2.67]；P=0.008）、室性心律失常（aOR 3.17[1.01-9.89]；P=0.047）、氧依赖（aOR 2.41[1.64-3.55]；P<0.001）、心脏骤停（aOR 2.61[1.63-4.18]；P<0.001）和肠梗阻（aOR 2.61[1.45-4.69]；P=0.001）。
患有SSc的COVID-19住院患者更有可能发生院内并发症，且死亡风险更高。
